Alembic Pharmaceuticals clears FDA inspection at Vadodara facility

Alembic Pharmaceuticals Limited said that an inspection by the US Food and Drug Administration (FDA) was completed at its bioequivalence facility in Vadodara, Gujarat.

According to the Indian pharma company, the FDA did not make any observations about the Vadodara bioequivalence facility.

Alembic Pharmaceuticals revealed that the FDA inspection was carried out from 17 October 2022 to 21 October 2022.

Based in Vadodara, Alembic Pharmaceuticals manufactures and markets formulations, generics, and active pharmaceutical ingredients (APIs).